openPR Logo
Press release

The Law Offices of James Sokolove Highlights Trajedy of Trasylol

02-22-2008 02:22 PM CET | Politics, Law & Society

Press release from: The Law Offices of James Sokolove

Newton, Mass., Feb. 21, 2008 − The Law Offices of James Sokolove (LOJS), dedicated to providing equal access to the civil justice system, expressed its continuing dismay following a recent report on the tragedy linked to the drug Trasylol®. According to a recent segment that aired on the CBS program 60 Minutes, the drug’s manufacturer failed to adequately warn doctors and patients of the risks involved in its use resulting in thousands of deaths and cases of kidney failure.

Manufactured by Bayer Pharmaceuticals, Trasylol is used to control bleeding in patients undergoing coronary-artery bypass grafting (CABG) surgery. In further reporting on February 21, 2008, the New York Times cites 2 new studies in the New England Journal of Medicine on this drug, one of which from Duke University notes that 6.4 percent of CABG patients who were given Trasylol died within 30 days of the surgery, a rate nearly 2.5 times higher than patients who got another drug or who received no treatment.

“Heart surgery patients who received this drug in the operating room may never have connected their subsequent kidney failure with Trasylol administration,” says Attorney Jim Sokolove, principal and founder of the LOJS. “When you consider that this drug was on the market for fourteen years the scope of individual tragedies is immense and needless.”

Although the drug was removed from the market in 2007, early safety concerns were raised by a German researcher who discovered severe kidney damage in animals given Trasylol and subsequent studies yielded similar results in humans.

In 2006, Dr. Dennis Mangano completed an observational study of 5,065 patients in 17 countries. The results of Mangano’s study, which were published in the New England Journal of Medicine, also showed an increased rate of kidney failure and death in patients who were treated with Trasylol. Dr. Mangano filed a report with the Food and Drug Administration (FDA) and that agency advised doctors of those findings.

In 2007, a clinical trial conducted by the Canadian government was halted early due to the high number of deaths among subjects who took Trasylol. The FDA convinced Bayer to stop marketing the drug, and Bayer finally removed Trasylol from the market in November 2007. Today, surgeons use the drug only under special circumstances and the manufacturer recommends that notification of its administration be given to the patient and placed in their medical chart.

“For a drug manufacturer to withhold information that could have saved as many as 1,000 lives per month over a period of two years is incomprehensible,” Sokolove says. “They put innocent consumers at risk with their shameless favor of profits over patients.”

The Law Offices of James Sokolove
1340 Centre Street
Newton Center, MA 02459
Ellen Fletcher
617 467 6967

About The Law Offices of James Sokolove
For almost 30 years, The Law Offices of James Sokolove (LOJS) has focused on reinventing how people obtain legal services. Equality of access, irrespective of ethnicity or income, and superior quality of representation and service within our civil justice system is our mission. Within an ever-changing legal profession, the LOJS business model is a proven success strategically matching specific client needs with particular law firm expertise and service quality. LOJS is the nation’s largest and fastest growing marketer of legal services.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Law Offices of James Sokolove Highlights Trajedy of Trasylol here

News-ID: 38068 • Views: 1424

More Releases from The Law Offices of James Sokolove

The Law Offices of James Sokolove (LOJS), dedicated to providing greater access to the civil justice system, introduced more features to the ground-breaking community site, Mesothelioma Resource Center (MesoRC) to include a Community Marketplace and a Tribute Wall. The MesoRC website also provides a powerful one-stop informational resource for victims and families affected by this rare and aggressive cancer. Since its launch in September 2007, the site has seen continuing
The Law Offices of James Sokolove Adds CFO
The Law Offices of James Sokolove (LOJS), a company dedicated to reinventing how people access to the civil justice system, today announced the creation of a new executive role with the appointment of Rob Bunn as chief financial officer. After consulting for LOJS since 2004, Rob will now play a central role in developing and evaluating the Company’s financial direction and capital market activities. “Rob’s in-depth knowledge of LOJS and
The Law Offices of James Sokolove (LOJS), dedicated to providing equal access to the civil justice system, conveyed its deep concerns at reports of deadly side effects linked to the hormonal contraceptive ring device, NuvaRing. Used by 1.5 million women worldwide, the device has been associated with a significantly increased risk of blood clots, strokes, heart attacks, and in extreme cases, death. “Data has been available since 1995 which clearly
The Law Offices of James Sokolove Warns Consumers of Fentanyl Dangers
The Law Offices of James Sokolove (LOJS), dedicated to providing equal access to the civil justice system, cites the mounting evidence of danger associated with the use of the fentanyl prescription pain patch. This week Johnson & Johnson (J&J) and Novartis AG\'s Sandoz recalled 25-micrograms/hour Duragesic®-brand transdermal pain patches in the U.S. and Canada due to the risk of accidental overdose resulting from manufacturing defects in the patch.

All 5 Releases

More Releases for Trasylol

Aprotinin Market Is Booming Across the Globe Explored in Latest Report 2019-2024 …
Aprotinin Market 2019 Report analyses the Industry Status, Size, Share, Emerging Trends, Growth Opportunity, Competition landscape and Forecast to 2024. This report also provides data on Patterns, Improvements, Target Business Sectors, Limits and Advancements. Global Aprotinin Market overview: The report " Aprotinin Market” The quick adoption of advanced Analytics and Visualization and the expand use of outward data sources are the major drivers of the Aprotinin Market. The report high Point, Potential
Aprotinin Market will surge at 4.6% CAGR up to 2025: QY Research, Inc.
QY Research has come up with a newly published report on global Aprotinin market in its database that provides an in-depth analysis of the key market insights, its future trends, and developments, profiles of leading players, key restraints and drivers, segmentation and forecasting. The report highlights the Aprotinin market size and CAGR of the important segments, thus providing quick relevant information about the global Aprotinin market. Aprotinin, also known as bovine
Emerging Trends in Aprotinin Market 2018 and Global Foreseen Till 2022 | Analysi …
“Global Aprotinin Market Report 2018” report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market. Global Aprotinin Market Overview: The report spread across 125 pages is an overview of the Global Aprotinin Market Report 2018. The Global
Antifibrinolytic Drugs Market Size & Share by Application, Type and Region - Glo …
MarketResearchReports.Biz announces addition of new report "Antifibrinolytic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" to its database. The main objective of this report is to define, describe, and forecast the global “Antifibrinolytic Drugs” market on the basis of types of applications, major sectors, deployment models, organization size, and regions. The report contains an analysis of the major factors influencing the growth of the
Antifibrinolytic Drugs Market: Report Scope and Market Segmentation 2017 - 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.
Antifibrinolytic Drugs Market Will Generate New Growth Opportunities By 2025
Tissue damage leads to rupture of vessels which triggers hemostatic mechanism. Hemostasis is a physiological mechanism of the body, wherein vessels contract, platelet plugs are formed, and coagulation starts, resulting in a stable fibrin network. Fibrinolysis is activated during this mechanism. Fibrinolysis is a physiological process in which blood clots are dissolved and tissue damage is remolded. Antifibrinolytic drugs are used to induce clot formation and to prevent blood loss